Table 1.
Information of DC–CIK immunotherapy
| Included studies | Therapeutic regimen | Administration route | Culture conditions | Cell dose (cycles) |
|---|---|---|---|---|
| Ding (2013)14 | CT (VD), CIK | Intravenous infusion | IFN-γ, IL-1α, IL-2, CD3 | >1×1010 (ND) |
| Gao (2015)15 | CT (VDP/DEV/DCEV), DC–CIK | Intravenous infusion | ND | 2.5–5×109 (>3 cycles) |
| Lu (2015)16 | CT (VCD), DC–CIK | Intravenous infusion | IFN-γ, IL-1α, IL-2, CD3, GM-CSF, IL-4 | 1.2–2.4×1010 (≧2 cycles) |
| Sun (2012)17 | CT (Thd), DC–CIK | Intravenous infusion | IFN-γ, IL-1α, IL-2, CD3, GM-CSF, IL-4 | 1×109–10 (2 cycles) |
| Tan (2016)18 | CT (DEV), CIK | Intravenous infusion | IFN-γ, IL-12, CD3 | ND (3 cycles) |
| Wang (2015)19 | CT (VD/VDT/VCD/MVP), DC–CIK | Intravenous infusion | IFN-γ, IL-1α, IL-12, CD3, GM-CSF, IL-4 | 1.5–3×1010 (>3 cycles) |
| Yan (2014)20 | CT (DEV/PM/DCEV/VDP), DC–CIK | Intravenous infusion | ND | 2–5×109 (>3 cycles) |
| Ye (2016)21 | CT (ND), DC–CIK | Intravenous infusion | ND | ND |
| Yu (2016)22 | CT (VD), DC–CIK | Intravenous infusion | ND | 1.2–3×1010 (≥3 cycles) |
| Zhao (2015)23 | CT (VD), DC–CIK | Intravenous infusion | IFN-γ, IL-1α, IL-12, CD3, GM-CSF, IL-4 | 1.2–3×1010 (>3 cycles) |
| Zhao (2016)24 | CT (VD), DC–CIK | Intravenous infusion | IFN-γ, IL-1α, IL-12, CD3, GM-CSF, IL-4 | 1.2–3×1010 (>3 cycles) |
| Zhong (2012)25 | CT (MP/DEV/DCEV/VEDM/VD/VED), DC–CIK | Intravenous infusion | IFN-γ, IL-1α, IL-12, CD3, GM-CSF, IL-4 | 1.5–3×1010 (>3 cycles) |
Abbreviations: CIK, cytokine-induced killer cells; CT, chemotherapy; DC–CIK, dendritic cells and CIK; DCEV, dexamethasone + cytoxan + epirubicin + vindesine; DEV, dexamethasone + epirubicin + vindesine; MP, melphalan + prednisone; MVP, melphalan + velcade + prednisone; ND, nondetermined; Thd, thalidomide; VCD, velcade + cytoxan + dexamethasone; VD, velcade + dexamethasone; VDP, velcade + dexamethasone + pirarubicin; VDT, velcade + dexamethasone + thalidomide; VED, velcade + epirubicin + dexamethasone; VEDM, vincristine + epirubicin + dexamethasone + melphalan.